intensive treatment.<\/em><\/p>\n <\/p>\n
Lyon (France), November 15th, 2016 \u2013 MaaT Pharma, the French pioneer company that develops innovative autologous fecal microbiota transfer based treatments for serious complications in Acute Myeloid Leukemia, Bone and Joint Infections with unmet medical needs, announces that an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company\u2019s Phase 1b study in the prevention of dysbiosis complications with autologous fecal microbiota transfer (AFMT) in Acute Myeloid Leukemia (AML) and the DSMB confirms that no safety issue occurs during the course of the trial and that enrollment will continue as planned until completion.<\/p>\n
<\/p>\n
A DSMB is a committee of independent clinical research experts who review data in ongoing clinical trials with particular attention to safety. As per study protocol, the DSMB meets at least 3 times during the trial, first after the inclusion of 3 to 5 patients to review the safety data of the ODYSSEE trial and subsequently issues recommendations on the conduct of the study.<\/p>\n
<\/p>\n
AML are rare cancers, but potentially fatal in the adults. MaaT Pharma proposes using AFMT to AML patients aged 18 to 75 treated with intensive chemotherapy and antibiotics, therapeutics, which are known to deeply impact the gut microbial composition and to have severe clinical consequences. The purpose of AFMT is to restore the balance of the intestinal microbiome and thereby eradicate treatment-induced multi-drug resistant bacteria (MDRB), infection-related complications, as well as scarring of the gastrointestinal tract.[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/1″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_highlighted_text color_type=\u00a0\u00bbregular\u00a0\u00bb highlight_color=\u00a0\u00bb#f2c836″ style=\u00a0\u00bbhalf_text\u00a0\u00bb]About MaaT Pharma<\/strong><\/em><\/p>\nFounded at the end of 2014 and based in Lyon (France), MaaT Pharma (Microbiota as a Therapy) is a microbiome\u2013based pharmaceutical company revolutionizing and shaping individualized therapies to treat serious diseases linked to dysbiosis (gut microbiota imbalances). MaaT Pharma is currently developing its first candidate using its proprietary Autologous Fecal Microbiota Transfer Platform for patients suffering from leukemia, bone and joint infections, as these harsh treatments provoke dysbiosis. MaaT Pharma\u2019s revolutionary and rapid approach plays a considerable part in the evolution of individualized treatment therapies.<\/p>\n
For more information: https:\/\/maat.swebwp.oci.eu
\nFollow us on Twitter: @MaaT_Pharma
\nFollow us on LinkedIn: http:\/\/www.linkedin.com\/company\/maat-pharma[\/nectar_highlighted_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/1″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_btn size=\u00a0\u00bblarge\u00a0\u00bb open_new_tab=\u00a0\u00bbtrue\u00a0\u00bb button_style=\u00a0\u00bbregular\u00a0\u00bb button_color_2=\u00a0\u00bbAccent-Color\u00a0\u00bb color_override=\u00a0\u00bb#5bc0cc\u00a0\u00bb icon_family=\u00a0\u00bbiconsmind\u00a0\u00bb text=\u00a0\u00bbSee More\u00a0\u00bb icon_iconsmind=\u00a0\u00bbiconsmind-Mouse-Pointer\u00a0\u00bb margin_top=\u00a0\u00bb50″ url=\u00a0\u00bbhttps:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/09\/161115-MaaT-Pharma-DSMB-Press-release_v1.0.pdf\u00a0\u00bb][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"
Odyssee study focuses in prevention of dysbiosis complications.<\/p>\n","protected":false},"author":2,"featured_media":4438,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[54],"class_list":{"0":"post-4597","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-communiques-de-presse-fr","8":"year_press-54"},"acf":[],"yoast_head":"\n
MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"Odyssee study focuses in prevention of dysbiosis complications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-15T15:57:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-25T14:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1441\" \/>\n\t<meta property=\"og:image:height\" content=\"766\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study\",\"datePublished\":\"2016-11-15T15:57:50+00:00\",\"dateModified\":\"2023-09-25T14:04:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/\"},\"wordCount\":871,\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/\",\"name\":\"MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\",\"datePublished\":\"2016-11-15T15:57:50+00:00\",\"dateModified\":\"2023-09-25T14:04:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\",\"contentUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\",\"width\":1441,\"height\":766},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/maat.swebwp.oci.eu\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - MaaT Pharma","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - MaaT Pharma","og_description":"Odyssee study focuses in prevention of dysbiosis complications.","og_url":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/","og_site_name":"MaaT Pharma","article_published_time":"2016-11-15T15:57:50+00:00","article_modified_time":"2023-09-25T14:04:21+00:00","og_image":[{"width":1441,"height":766,"url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","type":"image\/jpeg"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#article","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study","datePublished":"2016-11-15T15:57:50+00:00","dateModified":"2023-09-25T14:04:21+00:00","mainEntityOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/"},"wordCount":871,"publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/","url":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/","name":"MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - MaaT Pharma","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","datePublished":"2016-11-15T15:57:50+00:00","dateModified":"2023-09-25T14:04:21+00:00","breadcrumb":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage","url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","contentUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","width":1441,"height":766},{"@type":"BreadcrumbList","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/maat.swebwp.oci.eu\/fr\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study"}]},{"@type":"WebSite","@id":"https:\/\/maat.swebwp.oci.eu\/#website","url":"https:\/\/maat.swebwp.oci.eu\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/maat.swebwp.oci.eu\/#organization","name":"Maat Pharma","url":"https:\/\/maat.swebwp.oci.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/4597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/comments?post=4597"}],"version-history":[{"count":0,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/4597\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media\/4438"}],"wp:attachment":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media?parent=4597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/categories?post=4597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/tags?post=4597"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/category_press?post=4597"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/year_press?post=4597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}